Prophylactic azithromycin for COPD

A team of US professors reviewed the latest clinical studies, the pharmacology and adverse effects of the antibiotic – recently linked with an increased absolute risk of cardiovascular and all-cause mortality – to conclude that current COPD management guidelines should be reviewed to include prophylactic antibiotics.

COPD is the third leading cause of death and disability in the US but the use of azithromycin has not been endorsed by any of the leading pulmonary and infectious disease organisations, they noted.

However its use had &ldquo